OBJECTIVE: To analyse B cell activating factor (BAFF) receptor (BAFF-R) expression on peripheral lymphocytes from patients with primary Sjögren's syndrome (pSS) and systemic lupus erythematosus (SLE). PATIENTS AND METHODS: Peripheral blood mononuclear cells from 20 patients with pSS, 19 patients with SLE and 15 controls were examined by flow cytometry to investigate BAFF-R mean fluorescence intensity (MFI) on lymphocytes. BAFF-R mRNA level from isolated blood B cells of nine patients with pSS and eight controls was assessed by real-time quantitative reverse transcription-PCR. BAFF serum level was determined by ELISA. RESULTS: In all subjects, BAFF-R was expressed on all naïve CD27- and memory CD27+ B-cells and was present on <0.5% of T cells. The expression of BAFF-R on B cells was significantly decreased in patients with pSS as compared with controls (MFI = 7.8 vs 10.6, p = 0.001), and was intermediate in patients with SLE (MFI = 9.5). Serum BAFF level was inversely correlated with BAFF-R MFI (p = 0.007), but not because of competition between endogenous BAFF (at observed concentrations in patients) and the monoclonal antibody (11C1) detecting BAFF-R. BAFF-R mRNA levels did not differ between patients with pSS and controls (p = 0.48). BAFF-R MFI decreased after overnight culture with recombinant human BAFF (from 32.5 to 25.4, p = 0.03). Contrary to the serum BAFF level, BAFF-R expression was correlated with extraglandular involvement in pSS and SLE Disease Activity Index. CONCLUSIONS: BAFF-R expression is reduced on peripheral B cells of patients with pSS and SLE. This down-regulation occurs through a post-transcriptional mechanism and could be the consequence of chronic increase in BAFF. BAFF-R levels on B cells could be a novel activity biomarker in autoimmune diseases.
OBJECTIVE: To analyse B cell activating factor (BAFF) receptor (BAFF-R) expression on peripheral lymphocytes from patients with primary Sjögren's syndrome (pSS) and systemic lupus erythematosus (SLE). PATIENTS AND METHODS: Peripheral blood mononuclear cells from 20 patients with pSS, 19 patients with SLE and 15 controls were examined by flow cytometry to investigate BAFF-R mean fluorescence intensity (MFI) on lymphocytes. BAFF-R mRNA level from isolated blood B cells of nine patients with pSS and eight controls was assessed by real-time quantitative reverse transcription-PCR. BAFF serum level was determined by ELISA. RESULTS: In all subjects, BAFF-R was expressed on all naïve CD27- and memory CD27+ B-cells and was present on <0.5% of T cells. The expression of BAFF-R on B cells was significantly decreased in patients with pSS as compared with controls (MFI = 7.8 vs 10.6, p = 0.001), and was intermediate in patients with SLE (MFI = 9.5). Serum BAFF level was inversely correlated with BAFF-R MFI (p = 0.007), but not because of competition between endogenous BAFF (at observed concentrations in patients) and the monoclonal antibody (11C1) detecting BAFF-R. BAFF-R mRNA levels did not differ between patients with pSS and controls (p = 0.48). BAFF-R MFI decreased after overnight culture with recombinant humanBAFF (from 32.5 to 25.4, p = 0.03). Contrary to the serum BAFF level, BAFF-R expression was correlated with extraglandular involvement in pSS and SLE Disease Activity Index. CONCLUSIONS:BAFF-R expression is reduced on peripheral B cells of patients with pSS and SLE. This down-regulation occurs through a post-transcriptional mechanism and could be the consequence of chronic increase in BAFF. BAFF-R levels on B cells could be a novel activity biomarker in autoimmune diseases.
Authors: P A Moore; O Belvedere; A Orr; K Pieri; D W LaFleur; P Feng; D Soppet; M Charters; R Gentz; D Parmelee; Y Li; O Galperina; J Giri; V Roschke; B Nardelli; J Carrell; S Sosnovtseva; W Greenfield; S M Ruben; H S Olsen; J Fikes; D M Hilbert Journal: Science Date: 1999-07-09 Impact factor: 47.728
Authors: Peter Szodoray; Stig Jellestad; Philip Alex; Tong Zhou; Patrick C Wilson; Michael Centola; Johan G Brun; Roland Jonsson Journal: J Clin Immunol Date: 2004-11 Impact factor: 8.317
Authors: J-E Gottenberg; M Busson; J Cohen-Solal; F Lavie; K Abbed; R P Kimberly; J Sibilia; X Mariette Journal: Ann Rheum Dis Date: 2005-01-07 Impact factor: 19.103
Authors: P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp Journal: J Exp Med Date: 1999-06-07 Impact factor: 14.307
Authors: Ana Henriques; Isabel Silva; Luís Inês; M Margarida Souto-Carneiro; M Luísa Pais; Hélder Trindade; José António Pereira da Silva; Artur Paiva Journal: Clin Exp Med Date: 2015-04-18 Impact factor: 3.984
Authors: Ruoyi Jiang; Miriam L Fichtner; Kenneth B Hoehn; Minh C Pham; Panos Stathopoulos; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor Journal: JCI Insight Date: 2020-07-23
Authors: Rita R Barbosa; Susana L Silva; Sara P Silva; Alcinda C Melo; M Conceição Pereira-Santos; João T Barata; Lennart Hammarström; Marília Cascalho; Ana E Sousa Journal: J Clin Immunol Date: 2014-05-09 Impact factor: 8.317
Authors: Kabir Matharu; Kol A Zarember; Beatriz E Marciano; Douglas B Kuhns; Christine Spalding; Mary Garofalo; Thomas Dimaggio; Tyra Estwick; Chiung-Yu Huang; Danielle Fink; Debra L Priel; Thomas A Fleisher; Steven M Holland; Harry L Malech; John I Gallin Journal: Clin Immunol Date: 2013-05-22 Impact factor: 3.969